Similar articles

• Single-center experience of 60 consecutive simultaneous pancreas-kidney transplants using mycophenolate mofetil and tacrolimus as primary maintenance immunotherapy.

  Kaufman DB, Leventhal JR, Stuart J, Parker M, Abecassis M, Fryer JP, Stuart FP. Kaufman DB, et al. Transplant Proc. 1999 Feb-Mar;31(1-2):615-6. doi: 10.1016/s0041-1345(98)01581-4. Transplant Proc. 1999. PMID: 10083261 Clinical Trial. No abstract available.
• Mycophenolate mofetil with lower cyclosporine dose in high-risk renal transplant recipients.

  Esmeraldo RM, Donadi MO, Oliveira ML, Ponte CN, Pinheiro PM. Esmeraldo RM, et al. Transplant Proc. 1999 Nov;31(7):3007-8. doi: 10.1016/s0041-1345(99)00644-2. Transplant Proc. 1999. PMID: 10578367 No abstract available.
• Prospective study of mycophenolate mofetil for the prevention of acute rejection in living donor renal allograft recipients.

  Park K, Kim SI, Moon JI, Kim YS, Kim MS. Park K, et al. Transplant Proc. 1998 Nov;30(7):3575. doi: 10.1016/s0041-1345(98)01141-5. Transplant Proc. 1998. PMID: 9838565 Clinical Trial. No abstract available.
• Antibody induction therapy in pancreas transplantation.

  Gruessner RW. Gruessner RW. Transplant Proc. 1998 Jun;30(4):1556-9. doi: 10.1016/s0041-1345(98)00356-x. Transplant Proc. 1998. PMID: 9636632 Review. No abstract available.
• Overview of transplantation immunology and the pharmacotherapy of adult solid organ transplant recipients: focus on immunosuppression.

  Bush WW. Bush WW. AACN Clin Issues. 1999 May;10(2):253-69; quiz 304-6. doi: 10.1097/00044067-199905000-00011. AACN Clin Issues. 1999. PMID: 10578712 Review.